Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Ross Camidge

Showing results (51-60 of 317) with videos related to

Pageof 32
Sort By:
Oncology (Williston Park, N.Y.)|December 13, 2006
From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancerGlen J Weiss, Paul A Bunn, D Ross Camidge
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2022
Managing Central Nervous System Spread of Lung Cancer: The State of the ArtDavid Chun Cheong Tsui, D Ross Camidge, Chad G Rusthoven
Clinical Lung Cancer|June 1, 2021
Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and CrizotinibJingran Ji, Anupam Mitra, D Ross Camidge, et al.
Clinical Lung Cancer|August 29, 2015
Cystic Brain Metastases Occurring in Anaplastic Lymphoma Kinase Gene Rearranged Non-Small-Cell Lung Cancer Patients Receiving CrizotinibVignesh Narayanan, M Justin Honce, Sanjana Mehrotra, et al.
Clinical Lung Cancer|December 22, 2023
Trial Design and Optimal Determination of CNS Activity of Small Molecule Targeted Therapy in NSCLCElaine M Jennings, D Ross Camidge, Shirish Gadgeel, et al.
Frontiers in Oncology|April 16, 2019
A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung CancerJose M Pacheco, D Ross Camidge, Robert C Doebele, et al.
Clinical and Translational Science|March 21, 2024
Mobocertinib: Mechanism of action, clinical, and translational scienceMichael J Hanley, D Ross Camidge, Robert J Fram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2010
Preclinical and clinical estimates of the basal apoptotic rate of a cancer predict the amount of apoptosis induced by subsequent proapoptotic stimuliLian Zhang, Brian D Kavanagh, Andrew M Thorburn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 31, 2016
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?Alexander Drilon, Federico Cappuzzo, Sai-Hong Ignatius Ou, et al.
Critical Reviews in Oncology/Hematology|October 25, 2011
The intersection between cannabis and cancer in the United StatesDaniel W Bowles, Cindy L O'Bryant, D Ross Camidge, et al.
Pageof 32

Showing results (51-60 of 317) with videos related to

Sort By:
Pageof 32
Oncology (Williston Park, N.Y.)|December 13, 2006
From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancerGlen J Weiss, Paul A Bunn, D Ross Camidge
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2022
Managing Central Nervous System Spread of Lung Cancer: The State of the ArtDavid Chun Cheong Tsui, D Ross Camidge, Chad G Rusthoven
Clinical Lung Cancer|June 1, 2021
Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and CrizotinibJingran Ji, Anupam Mitra, D Ross Camidge, et al.
Clinical Lung Cancer|August 29, 2015
Cystic Brain Metastases Occurring in Anaplastic Lymphoma Kinase Gene Rearranged Non-Small-Cell Lung Cancer Patients Receiving CrizotinibVignesh Narayanan, M Justin Honce, Sanjana Mehrotra, et al.
Clinical Lung Cancer|December 22, 2023
Trial Design and Optimal Determination of CNS Activity of Small Molecule Targeted Therapy in NSCLCElaine M Jennings, D Ross Camidge, Shirish Gadgeel, et al.
Frontiers in Oncology|April 16, 2019
A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung CancerJose M Pacheco, D Ross Camidge, Robert C Doebele, et al.
Clinical and Translational Science|March 21, 2024
Mobocertinib: Mechanism of action, clinical, and translational scienceMichael J Hanley, D Ross Camidge, Robert J Fram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2010
Preclinical and clinical estimates of the basal apoptotic rate of a cancer predict the amount of apoptosis induced by subsequent proapoptotic stimuliLian Zhang, Brian D Kavanagh, Andrew M Thorburn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 31, 2016
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?Alexander Drilon, Federico Cappuzzo, Sai-Hong Ignatius Ou, et al.
Critical Reviews in Oncology/Hematology|October 25, 2011
The intersection between cannabis and cancer in the United StatesDaniel W Bowles, Cindy L O'Bryant, D Ross Camidge, et al.
Pageof 32